• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New drug shows promise in preventing heart attacks
Conclusion This is a high-quality, well-conducted randomised controlled trial conducted in a very large number of people across multiple countries. To date, it's remained uncertain whether evolocumab reduces the risk of cardiovascular events. This study provides good evidence that the drug reduces the risk of major cardiovascular events in people with high LDL cholesterol levels, and with a high risk of having a cardiovascular event, who are already taking statins. The follow-up is limited to around two years, during which roughly 1 in 10 people experienced a cardiovascular event. The reduction in risk was shown to inc...
Source: NHS News Feed - March 20, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news